

# Accepted Manuscript

Genetic analysis of the *SOD1* and *C9ORF72* genes in Hungarian patients with amyotrophic lateral sclerosis

Kornélia Tripolszki, Bernadett Csányi, Dóra Nagy, Antonia Ratti, Cinzia Tiloca, Vincenzo Silani, Éva Kereszty, Nóra Török, László Vécsei, József I. Engelhardt, Péter Klivényi, Nikoletta Nagy, Márta Széll

PII: S0197-4580(17)30024-6

DOI: [10.1016/j.neurobiolaging.2017.01.016](https://doi.org/10.1016/j.neurobiolaging.2017.01.016)

Reference: NBA 9830

To appear in: *Neurobiology of Aging*


Received Date: 23 November 2016

Revised Date: 16 January 2017

Accepted Date: 20 January 2017

Please cite this article as: Tripolszki, K., Csányi, B., Nagy, D., Ratti, A., Tiloca, C., Silani, V., Kereszty, É., Török, N., Vécsei, L., Engelhardt, J.I., Klivényi, P., Nagy, N., Széll, M., Genetic analysis of the *SOD1* and *C9ORF72* genes in Hungarian patients with amyotrophic lateral sclerosis, *Neurobiology of Aging* (2017), doi: 10.1016/j.neurobiolaging.2017.01.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Genetic analysis of the *SOD1* and *C9ORF72* genes in Hungarian patients with amyotrophic lateral sclerosis**

Kornélia Tripolszki<sup>1</sup>, Bernadett Csányi<sup>2</sup>, Dóra Nagy<sup>1</sup>, Antonia Ratti<sup>3,4</sup>, Cinzia Tiloca<sup>3</sup>, Vincenzo Silani<sup>3,4</sup>, Éva Kereszty<sup>2</sup>, Nóra Török<sup>5</sup>, László Vécsei<sup>5,6</sup>, József I. Engelhardt<sup>5</sup>, Péter Klivényi<sup>5</sup>, Nikoletta Nagy<sup>1,7\*\*</sup>, Márta Széll<sup>1,7#</sup>

<sup>1</sup>Department of Medical Genetics, University of Szeged, Szeged, Hungary

<sup>2</sup>Department of Forensic Medicine, University of Szeged, Szeged, Hungary

<sup>3</sup>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy

<sup>4</sup>Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, Università degli Studi di Milano, Milan, Italy

<sup>5</sup>Department of Neurology, University of Szeged, Szeged, Hungary

<sup>6</sup>MTA-SZTE Neuroscience Research Group, University of Szeged, Szeged, Hungary

<sup>7</sup>MTA SZTE Dermatological Research Group, University of Szeged, Szeged, Hungary

#These two authors contributed equally to this work.

**Corresponding author:** Nikoletta Nagy MD PhD, Department of Medical Genetics, University of Szeged, 6 Somogyi Bela Street, 6724 Szeged, HUNGARY, Tel.: +36-62-545134, Email: [nikoletta.nagy@gmail.com](mailto:nikoletta.nagy@gmail.com), [nagy.nikoletta@med.u-szeged.hu](mailto:nagy.nikoletta@med.u-szeged.hu)

**Abstract**

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the death of motor neurons. To date, more than 20 genes have been implicated in ALS, and of these, the two most frequently mutated are the *superoxide dismutase 1 (SOD1)* gene and the *chromosome 9 open reading frame 72 (C9ORF72)* gene. In this study, we aimed to investigate the contribution of these two Mendelian genes to the development of the disease in Hungarian ALS patients (n=66). Direct sequencing of the *SOD1* gene revealed a novel (p.Lys91ArgfsTer8) and three recurrent heterozygous mutations (p.Val14Met, p.Asp90Ala, p.Leu144Phe) in five patients. The novel p.Lys91ArgfsTer8 mutation led to a frameshift causing the addition of eight new amino acids, including a premature stop codon at position 99. The GGGGCC hexanucleotide repeat expansion of the *C9ORF72* gene was present in one ALS patient. This study represents the first genetic analysis of two major ALS causative genes in a cohort of Hungarian ALS patients and contributes to the further understanding of the genetic and phenotypic diversity of ALS.

**Key words:** ALS, *SOD1*, *C9ORF72*, mutation screening, repeat expansion

## 1. Introduction

Amyotrophic lateral sclerosis (ALS; ORPHA803), also known as "Lou Gehrig's disease", is a fatal, neurodegenerative disorder characterized by the death of motor neurons in the brain, brainstem and spinal cord, resulting in fatal paralysis (Morrison and Harding, 1994). Familial forms account for about 10% of ALS cases, while other cases are sporadic (Strong *et al.*, 1991; Hewitt *et al.*, 2010). Familial forms are mainly transmitted in a Mendelian pattern of autosomal dominant inheritance (Hardiman *et al.*, 2011). Regarding its genetic background, more than 20 genes have been implicated in the development of ALS (ALSoD Database, <http://alsod.iop.kcl.ac.uk>).

Among the ALS causative genes, *superoxide dismutase 1 (SOD1)* is one of the most commonly mutated genes and accounts for approximately 12–23% of the familial and up to 7% of the sporadic ALS forms (Andersen, 2006). *SOD1* gene encodes the Cu/Zn superoxide dismutase enzyme, which catalyzes the inactivation of superoxide into oxygen and hydrogen peroxide, providing antioxidant defense (Smirnoff 1993). To date, more than 170 mutations have been reported for *SOD1* in the Amyotrophic Lateral Sclerosis Online Genetics Database (ALSoD Database; Abel *et al.*, 2012) since the gene was firstly associated to ALS in 1993 (Rosen *et al.*, 1993). *SOD1* mutations occur in all the five exons of the gene.

Another frequently mutated ALS gene is *chromosome 9 open reading frame 72 (C9ORF72)*, which – in addition to the *SOD1* mutations – is now recognized as the main cause of familial and sporadic ALS (Majounie *et al.*, 2012; Gijssels *et al.*, 2012; Ratti *et al.*, 2012; Smith *et al.*, 2013). A hexanucleotide (GGGGCC) repeat expansion (RE) located in the non-coding region of the gene that can reach up to 4400 units (normal range: 2-23 units) has been identified in patients with ALS and/or frontotemporal dementia. The GGGGCC RE contributes to 23–47% of familial ALS and to 4–5% of sporadic cases (Renton *et al.*, 2011; DeJesus-Hernandez *et al.*, 2011; Byrne *et al.*, 2012; Ratti *et al.*, 2012), with a frequency depending on geographical origin. Although the pathomechanism with which the hexanucleotide RE leads to the development of ALS has not been elucidated completely, both *C9orf72* haploinsufficiency gain of function mechanisms (driven by toxicity of sense and antisense RNA transcripts and derived dipeptide repeat proteins) have been reported (Taylor *et al.*, 2016).

In this study, we have investigated the contributions of the two most commonly mutated ALS genes, *SOD1* and *C9ORF72*, to the pathogenesis of the disease in Hungarian patients (n=66). This study represents the first genetic screening of ALS in Hungary, which adds novel data to the genetic and phenotypic diversity of this disease.

## 2. Patients and methods

### 2.1 Investigated individuals

The unrelated patients (n=66) included in this study were recruited from the Department of Neurology, University of Szeged, Szeged, Hungary, between 2010 and 2016. All patients fulfilled the El Escorial criteria for ALS (Brooks *et al.*, 2000). Of the 66 cases, only one patient reported other affected family members; the other 65 cases were considered sporadic. All patients were of Hungarian ancestry. The study was approved by the Internal Ethical Review Board of the University of Szeged. Written informed consent was obtained from all patients, and the study was conducted according to the Principles of the Declaration of Helsinki.

### 2.2 Genetic analyses

Blood samples were collected from all the enrolled individuals (n=66), and genomic DNA was isolated using a BioRobot EZ1 DSP Workstation (QIAGEN; Godollo, Hungary). The entire coding region of the *SOD1* gene and the flanking introns were amplified (primer sequences used were taken from the UCSC Genome Browser [www.genome.ucsc.edu](http://www.genome.ucsc.edu)). Direct sequencing of the PCR products was performed on an ABI 3100 sequencer and compared with the wild-type gene sequences at the Ensemble Genome Browser (<http://ensemble.org>). To identify known variations, we used ALS Online Genetics Database (<http://alsod.iop.kcl.ac.uk/>) (Abel *et al.*, 2012), 1000 Genomes Database ([www.1000genomes.org/](http://www.1000genomes.org/)), dbSNP (<http://www.ncbi.nlm.nih.gov/project/SNP>) and Exome Aggregation Consortium (ExAC) database (<http://exac.broadinstitute.org>). To predict the functional effects of novel mutations, the sequence variations were assessed by *in silico* prediction programs, such as SIFT (<http://sift.bii.a-star.edu.sg/>), Polyphen-2 (<http://genetics.bwh.harvard.edu/pph2>) and Mutation Taster (<http://mutationtaster.org>). To examine possible effects of the mutations on the three-dimensional (3-D) structure of the SOD1 protein, we used the Swiss-Model protein structure homology-modeling server (<http://swissmodel.expasy.org/>; SOD1 Protein Data Bank accession number 4b3e.1.A).

A two-step protocol was followed for the detection of the GGGGCC hexanucleotide RE in the *C9ORF72* gene. Fragment length analysis was performed using GeneMapper ID v3.2.1., and the samples producing a single peak product were further analyzed in the second step by repeat-primed PCR using an ABI Prism Genetic Analyzer (Applied Biosystems). The peaks were visualized using GeneMapper ID v3.2.1.

software (Akimoto *et al.*, 2014). The presence of the GGGGCC RE was observed as a saw-tooth pattern with 6-base pair periodicity.

To determine whether the single individual carrying the GGGGCC RE identified in this study also carried the “risk” haplotype, we selected the rs3849942 variant to be used as a marker for the “risk” haplotype for the patient and control genotypes. Rs3849942 genotyping was based on allelic discrimination assays using TaqMan chemistry following the manufacturer’s instructions (Life Technologies; Budapest, Hungary).

### 3. Results

The direct DNA sequencing approach identified four different mutations of the *SOD1* gene in 5 ALS patients: three known heterozygous missense mutations (c.43G>A p.Val14Met; c.272A>C p.Asp90Ala; c.435G>C p.Leu144Phe) and one novel mutation (c.275\_276delAA, p.Lys91ArgfsTer8) (Table 1).

The detected novel heterozygous mutation (c.275\_276delAA, p.Lys91ArgfsTer8) is located in the fourth exon of the *SOD1* gene (Figure 1a) and led to a frameshift with the insertion of 8 novel amino acids and the formation of premature stop codon at the new amino acid position 99. Analysis using Mutation Taster software predicted that the p.Lys91ArgfsTer8 mutation causes severe truncation of the encoded enzyme, and, thus, we hypothesize that this mutation is likely to be pathogenic (Figure 1b). The pathogenic role of the p.Lys91ArgfsTer8 mutation is further supported by the fact that it interferes with the integrity of the Cys57-Cys146 disulfide bond, and results in the weakening of the dimer interface.

The novel p.Lys91ArgfsTer8 *SOD1* mutation was not present in 110 healthy controls of Hungarian ancestry that we investigated, neither it is represented in mutation databases, including Single Nucleotide Polymorphism Database (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), 1000 Genomes ([www.1000genomes.org/](http://www.1000genomes.org/)), Exome Aggregation Consortium (ExAC) database (<http://exac.broadinstitute.org>) and the ALS Online Genetics Database (<http://alsod.iop.kcl.ac.uk/>) (Abel *et al.*, 2012).

This novel mutation was carried by a female Hungarian patient suffering from sporadic ALS with the latest onset but the fastest progression of the disease (Table 1). She had been cured from a breast cancer eight years before the onset of ALS and proved to be tumor free on following checkups. As first symptoms, the lower extremities became clumsy and weak because of spasticity and muscle atrophy. The calculated ALS Functional Rating Scale R (ALSFRS-R score; Cedarbaum *et al.*, 1999) was 39/48 at the first examination, which was carried out four months after the appearance of the first symptoms. Then,

the signs of upper and lower motor neuron damage developed fast together with bulbar and pseudobulbar symptoms. She was given 2x50 mg riluzole/day, nevertheless, her status deteriorated quickly, and she became tetraplegic with dysarthria and dysphagia. Respiratory failure developed due to the weakened respiratory muscles and she died at home.

The SOD1 p.Leu144Phe mutation is located in the fifth exon of the gene and was identified in two female ALS patients. One of the patients reported that her maternal grandfather had suffered from non-progressive paralysis and weakness for 20 years. The other patient reported that her paternal grandmother had suffered from a disease similar to her own. In this study, only the latter patient was therefore considered as having a familial form of the disease. She was the youngest one at the disease onset.

The p.Val14Met mutation is located in the first exon of the SOD1 gene and was present in an affected female patient who reported no family history of ALS. Her first symptoms appeared at the age of 62. This patient showed lower and upper motor neuron signs. The disease course was progressive and led to the patient's death within one year after disease onset.

The p.Asp90Ala mutation, which is the most prevalent SOD1 mutation in Europe (Andersen *et al.*, 1995; Al-Chalabi *et al.*, 1998; Andersen 2001), is located in the fourth exon of the SOD1 gene and was present in a female patient. The patient also carried the rs111273304 splice-donor variant (c.239+2T>A), which is of unknown significance, in heterozygous form. This patient had clinical features typically associated with this genotype, including a relatively long survival after onset (Andersen 2006).

Analysis of the C9orf72 gene identified GGGGCC RE in one out of 66 ALS patients. The average repeat number based on fragment-length analysis was 5 (range 2–17 repeats) in the remaining 65 patients, none of whom carried repeat expansion. The patient with the repeat expansion also carried the rs3849942 risk allele, which was previously described as a part of the Finnish "risk" haplotype (Laaksovirta *et al.*, 2010).

This latter patient (Table 1) reported the first symptoms of ALS six months before she presented to the neurological unit at age 65 with gradually increasing foot drop on the left side due to peroneal weakness. The ALSFRS-R was 44/48. Three years before admission, an adenoma of one of the parathyroid glands causing hyperparathyroidism was surgically removed but on admission the level of the parathyroid hormone in her serum was within normal ranges. A debate whether hyperparathyroidism can mimic ALS has been ongoing for the last 50 years (Jackson *et al.*, 1998).

#### 4. Discussion

In this study, we analyzed *SOD1* and *C9ORF72* genes in a cohort of 66 Hungarian ALS patients, including one single case with a reported familial history for the disease. We identified a novel and likely disease-causing heterozygous frameshift mutation (p.Lys91ArgfsTer8) in the *SOD1* gene. Three other heterozygous recurrent *SOD1* missense mutations (p.Val14Met, p.Asp90Ala and p.Leu144Phe) were also detected. *SOD1* mutations were detected in 7.5% (5/66) of our cohort, in line with literature data reporting that *SOD1* mutations account for approximately 0–7% patients with sporadic disease (Andersen, 2006).

The identified novel p.Lys91ArgfsTer8 *SOD1* mutation is associated with a typical ALS phenotype characterized by lower and upper motor neuron signs. The disease had a late onset at the age of 67 years and progressive course leading to the death of the patient within one year after the onset of the signs and symptoms of the disease. The two-base-pair deletion of the p.Lys91ArgfsTer8 *SOD1* mutation leads to a frameshift with the formation of a premature stop codon after the insertion of eight novel amino acids, causing a severe truncation of the protein (Figure 1b). This truncation abolishes the integrity of the intrachain C57–C146 disulfide bridge. Although most mutations in the *SOD1* gene are missense ones, a few deletions and insertions have been described previously causing truncations of different sizes and in most cases affecting also the C57–C146 disulfide bridge (<http://alsod.iop.kcl.ac.uk/>; Abel *et al.*, 2012). The most comprehensively studied truncation mutant is the Gly127insTGGG (G127X), carriers of which developed signs of motor neuron degeneration with a rapid disease course (Jonsson *et al.*, 2004). These observations correlate well with the clinical manifestations and course of ALS in the investigated Hungarian patient with the truncating p.Lys91ArgfsTer8 *SOD1* mutation. *SOD1* protein with truncating mutations exhibits structural instability causing misfolding in the mutated enzyme (Jonsson *et al.*, 2004) which can consequently aggregate in motor neurons and lead to the development of ALS (Forsberg *et al.*, 2011).

With the exception of the p.Asp90Ala *SOD1* mutation, the detected recurrent mutations are all associated with typical ALS phenotypes, characterized by lower and upper motor neuron signs, late onset and progressive disease course. In the case of the patient with the p.Asp90Ala heterozygous mutation, lower limb involvement and relatively long duration of the disease course was detected similarly to cases reported previously (Robberecht *et al.*, 1996; Andersen *et al.*, 2006). The p.Asp90Ala mutation is the most common *SOD1* mutation in Europe (Andersen 2001), and it can be inherited in either a dominant or recessive manner (Robberecht *et al.*, 1996).



The p.Leu144Phe missense mutation, which is the most prevalent mutation in the Balkan region (ALSoD), was detected in a familial and in a sporadic case. The clinical symptoms and the course of the disease were similar in these two patients. To note, the patient with a positive family history developed ALS symptoms at a relatively early age, whereas onset for the other patient was late. Although a significant number of patients with this mutation have lower limb onset (Corcia *et al.*, 2011), both of our patients developed upper and lower motor neuron signs. The rare p.Val14Met mutation was detected in an apparently sporadic case in a female patient with upper and lower motor neuron signs. None of the *SOD1* mutations detected in these ALS patients was identified in 110 healthy Hungarian controls.

*C9orf72* repeat expansion was detected only in one patient of 66. The patient carrying the RE variant also carried the previously described rs3849942 risk allele (Laaksovirta *et al.*, 2010; DeJesus-Hernandez *et al.*, 2011) in heterozygous form. According to earlier findings, the "A" allele of SNP rs3849942 was significantly associated to the expanded *C9ORF72* allele (DeJesus-Hernandez *et al.*, 2011). We screened 110 controls of Hungarian origin to establish the allele frequencies in this genomic position. The allele frequency of the minor allele in the Hungarian population (MAF (A) = 0.18) correlates well with the data from 1000 Genomes Database ([www.1000genomes.org/](http://www.1000genomes.org/)). We observed that the average repeat number was 5 (range: 2–17 repeats) in the remaining 65 patients who did not carry repeat expansions.

In conclusion, we performed the first genetic analysis of *SOD1* and *C9ORF72* genes in a cohort of Hungarian ALS patients. Our study further widens the geographic range for the origin of disease-causing heterozygous missense and frameshift mutations of the *SOD1* gene, which have already been implicated in ALS patients from different countries of origin. In this study, we identified the hexanucleotide RE of the *C9ORF72* gene only in one sporadic patient. These results suggest that the frequency of RE observed in the Hungarian ALS patients (1,5%) is significantly lower than in Western European populations (Majounie *et al.*, 2012; Ratti *et al.*, 2012; Fogh *et al.*, 2014), further demonstrating that the frequency of genetic factors for ALS varies among different geographic regions.

**Acknowledgements**

Funding of the study reported in the paper was provided by the Hungarian Brain Research Program [Grant No. KTIA\_13\_NAP-A-II/15, TÁMOP-4.2.2.A-11/1/KONV-2012-0052 and TÁMOP-4.2.2.A-11/1/KONV-2012-0035].

**Conflict of interest**

None to declare.

**References**

- Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSod: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. *Hum Mutat* 2012;33:1345-1351.
- Andersen PM, Nilsson P, Ala-Hurula V, Keränen ML, Tarvainen I, Haltia T, Nilsson L, Binzer M, Forsgren L, Marklund SL. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. *Nat Genet* 1995;10:61-6.
- Andersen PM, Spitsyn VA, Makarov SV, Nilsson L, Kravchuk OI, Bychkovskaya LS, Marklund SL. The geographical and ethnic distribution of the D90A CuZn-SOD mutation in the Russian Federation. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2001;2:63-9.
- Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. *CurrNeurolNeurosci Rep* 2006;6:37-46.
- Akimoto C, Volk AE, van Blitterswijk M, Van den Broeck M, Leblond CS, Lumbroso S, Camu W, Neitzel B, Onodera O, van Rheenen W, Pinto S, Weber M, Smith B, Proven M, Talbot K, Keagle P, Chesi A, Ratti A, van der Zee J, Alstermark H, Birve A, Calini D, Nordin A, Tradowsky DC, Just W, Daoud H, Angerbauer S, DeJesus-Hernandez M, Konno T, Lloyd-Jani A, de Carvalho M, Mouzat K, Landers JE, Veldink JH, Silani V, Gitler AD, Shaw CE, Rouleau GA, van den Berg LH, Van Broeckhoven C, Rademakers R, Andersen PM, Kubisch C. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. *J Med Genet* 2014;51:419-24.
- Al-Chalabi A, Andersen PM, Chioza B, Shaw C, Sham PC, Robberecht W, Matthijs G, Camu W, Marklund SL, Forsgren L, Rouleau G, Laing NG, Hulse PV, Siddique T, Leigh PN, Powell JF. Recessive

amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. *Hum Mol Genet* 1998;7:2045–2050.

Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000;1:293-299.

Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, Heverin M, Jordan N, Kenna K, Lynch C, McLaughlin RL, Iyer PM, O'Brien C, Phukan J, Wynne B, Bokde AL, Bradley DG, Pender N, Al-Chalabi A, Hardiman O. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. *Lancet Neurol* 2012;11:232–240.

Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). *J Neurol Sci* 1999;169:13-21.

Corcia P, Petiot P, Stevic Z, Vourc'h P, Morales R, Gordon PH, Pageot N, Andres C, Camu W. Respiratory onset in an ALS family with L144F SOD1 mutation. *J Neurol Neurosurg Psychiatry* 2011;82:747e749.

DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 2011;72:245-256.

Fogh I, Ratti A, Gellera C, Lin K, Tiloca C, Moskvina V, Corrado L, Soraru G, Cereda C, Corti S, Gentilini D, Calini D, Castellotti B, Mazzini L, Querin G, Gagliardi S, Del Bo R, Conforti FL, Siciliano G, Inghilleri M, Sacca F, Bongioanni P, Penco S, Corbo M, Sorbi S, Filosto M, Ferlini A, Di Blasio AM, Signorini S, Shatunov A, Jones A, Shaw PJ, Morrison KE, Farmer AE, Van Damme P, Robberecht W, Chio A, Traynor BJ, Sendtner M, Melki J, Meininger V, Hardiman O, Andersen PM, Leigh NP, Glass JD, Overste D, Diekstra FP, Veldink JH, van Es MA, Shaw CE, Weale ME, Lewis CM, Williams J, Brown RH, Landers JE, Ticozzi N, Ceroni M, Pegoraro E, Comi GP, D'Alfonso S, van den Berg LH, Taroni F, Al-Chalabi A, Powell J, Silani V and the SLAGEN Consortium and Collaborators. A genome-wide

association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. *Hum Mol Genet* 2014; 23:2220-2231.

Forsberg K, Andersen PM, Marklund SL, Brännström T. Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. *Acta Neuropathol* 2011;121:623-34.

Gijssels I, Van Langenhove T, van der Zee J, Sleegers K, Philtjens S, Kleinberger G, Janssens J, Bettens K, van Cauwenberghe C, Pereson S, Engelborghs S, Sieben A, De Jonghe P, Vandenberghe R, Santens P, De Bleecker J, Maes G, Bäumer V, Dillen L, Joris G, Couijt I, Corsmit E, Elinck E, Van Dongen J, Vermeulen S, Van den Broeck M, Vaerenberg C, Mattheijssens M, Peeters K, Robberecht W, Cras P, Martin JJ, De Deyn PP, Cruts M, Van Broeckhoven C. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. *Lancet Neurol* 2012;11:54–65.

Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. *Nat Rev Neurol* 2011;7:639-49.

Hewitt C, Kirby J, Highley JR, Hartley JA, Hibberd R, Hollinger HC, Williams TL, Ince PG, McDermott CJ, Shaw PJ. Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. *Arch Neurol* 2010;67: 455-461.

Jackson CE, Amato AA, Bryan WW, Wolfe GI, Sakhaee K, Barohn RJ. Primary hyperparathyroidism and ALS, is there a relation? *Neurology* 1998;50:1795-99.

Jonsson PA, Ernhill K, Andersen PM, Bergemalm D, Brannstrom T, Gredal O, Nilsson P, Marklund SL. Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. *Brain* 2004;127:73-88.

Laaksovirta H, Peuralinna T, Schymick JC, Scholz SW, Lai SL, Myllykangas L, Sulkava R, Jansson L, Hernandez DG, Gibbs JR, Nalls MA, Heckerman D, Tienari PJ, Traynor BJ. Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. *Lancet Neurol* 2010;9:978-985.

Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chio A, Restagno G, Nicolaou N, Simon-Sanchez J, van Swieten JC, Abramzon Y, Johnson JO, Sendtner M, Pampillet R, Orrell RW, Mead S, Sidle KC, Houlden H, Rohrer JD, Morrison KE, Pall H, Talbot K, Ansorge O, Chromosome 9-

ALS/FTD Consortium; French research network on FTLD/FTLD/ALS; ITALSGEN Consortium Hernandez DG, Arepalli S, Sabatelli M, Mora G, Corbo M, Giannini F, Calvo A, Englund E, Borghero G, Floris GL, Remes AM, Laaksovirta H, McCluskey L, Trojanowski JQ, Van Deerlin VM, Schellenberg GD, Nalls MA, Drory VE, Lu CS, Yeh TH, Ishiura H, Takahashi Y, Tsuji S, Le Ber I, Brice A, Drepper C, Williams N, Kirby J, Shaw P, Hardy J, Tienari PJ, Heutink P, Morris HR, Pickering-Brown S, Traynor BJ. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. *Lancet Neurol* 2012;11:323–30.

Morrison KE, Harding AE. Disorders of the motor neurone. *Baillieres Clin Neurol* 1994;3: 431–445.

Ratti A, Corrado L, Castellotti B, Del Bo R, Fogh I, Ceredag C, Tiloca C, D'Ascenzo C, Bagarotti A, Pensato V, Ranieri M, Gagliardi S, Calini D, Mazzini L, Taroni F, Corti S, Ceroni M, Oggioni GD, Lin K, Powell JF, Sorarù G, Ticozzi N, Comi GP, D'Alfonso S, Gellerad C, Silani V and the SLAGEN Consortium. *C9ORF72* repeat expansion in a large Italian ALS cohort: evidence of a founder effect *Neurobiol Aging* 2012;33:2528.e7–2528.e14.

Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Holtta-Vuori M, Ikonen E, Sulkava R, Benatar M, Wu J, Chio A, Restagno G, Borghero G, Sabatelli M, Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ. A hexanucleotide repeat expansion in *C9ORF72* is the cause of chromosome9p21-linked ALS-FTD. *Neuron* 2011;72:257-268.

Robberecht W, Aguirre T, Van den Bosch L, Tilkin P, Cassiman JJ, Matthijs G. D90A heterozygosity in the *SOD1* gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis. *Neurology* 1996;47:1336-9.

Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeld, Brian, Bergh RVD, Hung WY, Bird T, Deng G, Mulder DW, Smyth C, Laing NG,

Soriano E, Pericake Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, Brown JR, Robert H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* 1993;362:59-62.

Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van Den Berghe H, Van De Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. *Nature Genetics* 1995;10:436-44.

Smirnoff, N. The role of active oxygen in the response of plants to water deficit and desiccation. *New Phytologist* 1993;125:27-58.

Smith BN, Newhouse S, Shatunov A, Vance C, Topp S, Johnson L, Miller J, Lee Y, Troakes C, Scott KM, Jones A, Gray I, Wright J, Hortobágyi T, Al-Sarraj S, Rogeli B, Powell J, Lupton M, Lovestone S, Sapp PC, Weber M, Nestor PJ, Schelhaas HJ, Asbroek AA, Silani V, Gellera C, Taroni F, Ticonni N, Van Den Berg L, Veldink J, Van Damme P, Robberecht W, Shaw PJ, Kirby J, Pall H, Morrison KE, Morris A, de Belleruche J, Vianney de Jong JM, Baas F, Andersen PM, Landers J, Brown RH Jr, Weale ME, Al-Chalabi A, Shaw CE. The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. *Eur J Hum Genet* 2013;21:102-8.

Strong MJ, Hudson AJ, Alford WG. Familial amyotrophic lateral sclerosis, 1850-1989: a statistical analysis of the world literature. *Can J Neurol Sci* 1991;18:45-58.

Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. *Nature* 2016;539:197-206.

**Figure legends**

**Figure 1.** A novel p.Lys91ArgfsTer8 mutation in the Cu-Zn superoxide dismutase 1 (*SOD1*) gene identified in a Hungarian ALS patient

**(a)** The p.Lys91ArgfsTer8 novel frameshift mutation in the *SOD1* gene was identified by direct sequencing. **(b)** The crystallographic model shows that the novel frameshift mutation causes a severe truncation of the protein.

**Table 1.** Clinical data of Hungarian ALS patients carrying pathogenic variants in *SOD1* and *C9orf72* genes

Gene	Age of onset/gender	Mutation	Disease signs	Disease duration, years	Other diseases	ALS family history	Reference
<i>SOD1</i>	62/Female	p.Val14Met	LMN, UMN	1	Lumbar disc protrusions, atherosclerosis	No	Deng <i>et al.</i> 1995
<i>SOD1</i>	63/Female	p.Asp90Ala	LMN, UMN, B	12	Lumbar disc protrusions	No	Andersen <i>et al.</i> 1995
<i>SOD1</i>	67/Female	p.Lys91ArgfsTer8	LMN, UMN, B, PB	1	Breast cancer, hypertension, hypercholesterolemia, spondylosis and lumbar disc protrusions	No	<i>This study</i>
<i>SOD1</i>	29/Female	p.Leu144Phe	LMN, UMN	4	None reported	Yes	Deng <i>et al.</i> 1993
<i>SOD1</i>	46/Female	p.Leu144Phe	LMN, UMN, B	3	Lumbar disc protrusions	No	Deng <i>et al.</i> 1993
<i>C9orf72</i>	65/Female	Repeat Expansion	LMN, UMN	0,5	Hyperparathyroidism, multiple lipomas	No	Renton <i>et al.</i> , 2011; DeJesus <i>et al.</i> , 2011



Figure 1 a





Figure 1 b



ACCEPTED TEL

**Highlights**

- A novel (K91RfsX8) and three recurrent mutations (V14M, D90A, L144F) were detected
- The novel K91RfsX8 mutation causes severe truncation of the encoded enzyme
- The repeat expansion of the *C9ORF72* gene was present in one Hungarian patient
- First genetic analysis of two major ALS causative genes in Hungarian patients.